Phaxiam Therapeutics S A : PHAXIAM Therapeutics obtains authorizations to launch its phase 1 study in endocarditis infections caused by Staphylococcus aureus finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
24.10.2023 - Approval of study design by French ANSM and Ethics Committee Recruitment of 12 patients expected to start in Q4 2023 in 4 French centersFirst study results expected in mid-2024 Lyon (France) et Cambridge (MA, US), October 24, 2023, at 10:05 pm CEST . Seite 1
Approval of study design by French ANSM and Ethics Committee Recruitment of 12 patients expected to start in Q4 2023 in 4 French centersFirst study results expected in mid-2024 Lyon (France) et Cambridge (MA, US),
Investegate announcements from PHAXIAM Therapeutics obtains authorizations to launch its phase 1 study in endocarditis infections caused by Staphylococcus aureus